BR112013018744A2 - método para produzir um polipetídeo ou uma proteína recombinante - Google Patents

método para produzir um polipetídeo ou uma proteína recombinante

Info

Publication number
BR112013018744A2
BR112013018744A2 BR112013018744A BR112013018744A BR112013018744A2 BR 112013018744 A2 BR112013018744 A2 BR 112013018744A2 BR 112013018744 A BR112013018744 A BR 112013018744A BR 112013018744 A BR112013018744 A BR 112013018744A BR 112013018744 A2 BR112013018744 A2 BR 112013018744A2
Authority
BR
Brazil
Prior art keywords
treat
redifferentiated
animal
nucleic acid
producing
Prior art date
Application number
BR112013018744A
Other languages
English (en)
Other versions
BR112013018744B1 (pt
Inventor
Thereza D Deisher
Original Assignee
Avm Biotechnology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avm Biotechnology Llc filed Critical Avm Biotechnology Llc
Publication of BR112013018744A2 publication Critical patent/BR112013018744A2/pt
Publication of BR112013018744B1 publication Critical patent/BR112013018744B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

método para produzir um polipetídeo ou uma proteína recombinante a invenção fornece um método para produzir produtos de poliptídeo ou proteína e produtos de ácido nucléico níveis reduzidos de antigenicidade em um animal que está sendo tratado com um produto biológico. célula somáticas são isoladas de um animal, transformadas em células tronco pluripotentes, transfectadas com ácido (s) nucléico (s) de interesse, e rediferenciadas rumo a células somáticas conhecidas como tendo elevado nível de produtores do produto de ácido nucléico desejado. a invenção pode ser usada para derivar uma linhagem de células genéricas para tratar populações, linhagens de células específicas raciais para tratar grupos étnicos, ou linhagens de células específicas do paciente para tratar indivíduos. além disso, a invenção fornece um método que permite que células tronco pluripotentes induzidas sejam rediferenciadas rumo à sua célula tronco pluripotentes induzidas sejam rediferenciadas rumo à sua célula somática de origem, de tal forma que as células possam ser usadas para tratar terapeuticamente um animal sem resultar na formação de teratoma.
BR112013018744-1A 2011-01-03 2012-01-03 Método para produzir um polipetídeo ou uma proteína recombinante BR112013018744B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161429409P 2011-01-03 2011-01-03
US61/429,409 2011-01-03
US201161431376P 2011-01-10 2011-01-10
US61/431,376 2011-01-10
PCT/US2012/020084 WO2012094321A1 (en) 2011-01-03 2012-01-03 Personalized production of biologics and method for reprogramming somatic cells

Publications (2)

Publication Number Publication Date
BR112013018744A2 true BR112013018744A2 (pt) 2016-09-20
BR112013018744B1 BR112013018744B1 (pt) 2022-03-29

Family

ID=45563510

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013018744-1A BR112013018744B1 (pt) 2011-01-03 2012-01-03 Método para produzir um polipetídeo ou uma proteína recombinante

Country Status (14)

Country Link
US (2) US9512200B2 (pt)
EP (1) EP2661491A1 (pt)
JP (2) JP6223829B2 (pt)
KR (2) KR20140037036A (pt)
CN (2) CN108017692A (pt)
AU (1) AU2012204501B2 (pt)
BR (1) BR112013018744B1 (pt)
IL (1) IL227299B (pt)
MX (1) MX348776B (pt)
MY (1) MY161859A (pt)
RU (1) RU2595390C2 (pt)
SG (1) SG191836A1 (pt)
WO (1) WO2012094321A1 (pt)
ZA (1) ZA201305849B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916339B1 (en) 2013-10-31 2014-12-23 Vivex Biomedical, Inc. Spinal cord tissue dehydrated and micronized
WO2016088243A1 (ja) * 2014-12-05 2016-06-09 株式会社ニコン 判定装置、観察システム、観察方法、そのプログラム、細胞の製造方法、および細胞
US9402869B1 (en) 2015-03-27 2016-08-02 Vivex Biomedical, Inc. Treated neural tissue composition
US20180271908A1 (en) * 2015-05-01 2018-09-27 Cesca Therapeutics, Inc. Intramuscular administraton of autologous bone marrow for treatment
EP4026563A1 (en) * 2015-06-18 2022-07-13 Yeda Research and Development Co. Ltd Conditioning protocols and use of same for tissue regeneration
CN109563479A (zh) * 2016-05-25 2019-04-02 约翰霍普金斯大学 作为新型生物制剂递送平台的工程化的无核细胞和细胞外囊泡
WO2018173291A1 (ja) 2017-03-24 2018-09-27 本田技研工業株式会社 エンジン始動制御装置
US20190100730A1 (en) 2017-10-03 2019-04-04 Wallkill BioPharma, Inc. Treating diabetes with genetically modified beta cells
CA3092961A1 (en) * 2018-03-09 2019-09-12 Avrobio, Inc. Compositions and methods for treating parkinson's disease
CN111269878B (zh) * 2020-01-19 2022-02-11 深圳市北科生物科技有限公司 一种人多能干细胞转化为扩展多能干细胞的专用培养基及其应用
CN112143697B (zh) * 2020-10-08 2021-08-06 宁波希诺赛生物科技有限公司 一种促进胚胎干细胞增殖和分化的方法
US20220154148A1 (en) * 2020-11-18 2022-05-19 Xingxin Wang Methods for engineering human pluripotent stem cells for diabetes therapy by co-transduction

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
JP2002507407A (ja) 1998-03-23 2002-03-12 ザイモジェネティクス，インコーポレイティド 心臓由来幹細胞
US6150459A (en) 1998-04-13 2000-11-21 Massachusetts Institute Of Technology Comb polymers for regulating cell surface interactions
JP4817514B2 (ja) * 2001-03-09 2011-11-16 協和発酵キリン株式会社 新規動物細胞用ベクターおよびその使用
US20040033217A1 (en) 2002-05-31 2004-02-19 Padmavathy Vanguri Intraperitoneal delivery of genetically engineered mesenchymal stem cells
CA2965865C (en) 2002-07-18 2021-10-19 Merus N.V. Recombinant production of mixtures of antibodies
FR2878860A1 (fr) * 2004-12-08 2006-06-09 Vivalis Sa Lignees de cellules souches humaines derivees de cellules es et utilisations pour la production de vaccins et de proteines recombinantes
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
CN101432425A (zh) * 2006-01-04 2009-05-13 环球健康有限公司 通过转染由成体干细胞产生胰岛素分泌细胞的方法
US20090053182A1 (en) * 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
CA2660123C (en) * 2007-10-31 2017-05-09 Kyoto University Nuclear reprogramming method
WO2009091543A1 (en) * 2008-01-14 2009-07-23 Lindner Scott E An efficient orip/ebna-1 plasmid vector
US20090241206A1 (en) 2008-03-04 2009-09-24 University Of Iowa Research Foundation Methods for cloning ferrets and transgenic ferret models for diseases
US20110274670A1 (en) * 2008-06-13 2011-11-10 Myeong Jin Nam Mesenchymal stem cells which express human hepatic growth factor,manufacturing method thereof, and use thereof as therapeutic agent for liver diseases
WO2010022194A2 (en) * 2008-08-20 2010-02-25 Virxsys Corporation Compositions and methods for generation of pluripotent stem cells
ES2548993T3 (es) * 2009-01-26 2015-10-22 Pasteuria Bioscience, Inc. Nueva cepa de Pasteuria
WO2010117464A1 (en) * 2009-04-09 2010-10-14 Sangamo Biosciences, Inc. Targeted integration into stem cells
JP2010268789A (ja) * 2009-04-24 2010-12-02 Kumamoto Univ 細胞医薬の製造方法

Also Published As

Publication number Publication date
WO2012094321A4 (en) 2012-09-20
EP2661491A1 (en) 2013-11-13
SG191836A1 (en) 2013-08-30
CN103403152A (zh) 2013-11-20
ZA201305849B (en) 2014-10-29
MX2013007633A (es) 2015-07-14
US9512200B2 (en) 2016-12-06
JP6223829B2 (ja) 2017-11-01
JP2014501118A (ja) 2014-01-20
AU2012204501B2 (en) 2016-05-19
AU2012204501A1 (en) 2013-08-22
US20170081641A1 (en) 2017-03-23
KR20170120726A (ko) 2017-10-31
MY161859A (en) 2017-05-15
IL227299A0 (en) 2013-09-30
CN108017692A (zh) 2018-05-11
US10030230B2 (en) 2018-07-24
IL227299B (en) 2020-06-30
US20120171722A1 (en) 2012-07-05
BR112013018744B1 (pt) 2022-03-29
JP2018007660A (ja) 2018-01-18
KR20140037036A (ko) 2014-03-26
MX348776B (es) 2017-06-28
JP6373459B2 (ja) 2018-08-15
WO2012094321A1 (en) 2012-07-12
RU2013136357A (ru) 2015-02-10
RU2595390C2 (ru) 2016-08-27
NZ613888A (en) 2015-07-31

Similar Documents

Publication Publication Date Title
BR112013018744A2 (pt) método para produzir um polipetídeo ou uma proteína recombinante
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
EP4249036A3 (en) Methods and products for nucleic acid production and delivery
CY1125092T1 (el) Ιατρικη χρηση σχετικα με επεκταση τελομερους
MX2023001878A (es) Celulas modificadas geneticamente que comprenden un gen humano modificado de la region constante alfa del receptor de celulas t.
MX2021000210A (es) Metodos y productos para transfeccion de celulas.
MX2018005612A (es) Metodos y composiciones para la edicion genetica en celulas madre hematopoyeticas.
MX2018001617A (es) Composiciones de crispr-cas9 diseñados y metodos de uso.
MY172864A (en) Noninvasive detection of fetal genetic abnormality
WO2010141801A3 (en) Reprogramming t cells and hematophietic cells
MX354049B (es) Método rápido para la clonación y expresión de segmentos génicos de regiones variables de anticuerpos cognados.
EP2569453A4 (en) Nucleic Acid ISOLATION METHOD
MX2020011334A (es) Cultivo celular metabolicamente optimizado.
BR112013007862A2 (pt) ácidos nucleicos manipulados e métodos de uso dos mesmos.
PE20110358A1 (es) Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias
BR112014002027A2 (pt) gene pesticida axmi279 e métodos para a sua utilização
AR076541A1 (es) Mutantes de fgf21 y usos del mismo
EP3943092A3 (en) Compositions for use in inducing differentiation of human brown adipocyte progenitors
BR112014001909A2 (pt) gene da toxina axmi270 e métodos para a sua utilização
BR112013004700A2 (pt) método para prevenir ou tratar doenças ou distúrbios cardiovasculares
BR112014018610A2 (pt) alfa-amilase
BR112014001978A2 (pt) proteínas variantes axmi205 e métodos para a utilização das mesmas
MX2017005186A (es) Celulas madre neurales estables que comprenden un polinucleótido exógeno que codifica un factor de crecimiento y métodos de uso de las mismas.
MX2016005824A (es) Metodo de cultivo celular.
WO2016100820A3 (en) Fgf2 truncations and mutants and uses thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/01/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2755 DE 24-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.